Great Point Partners’s Protalix BioTherapeutics PLX Stock Holding History

Great Point Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-21,322	Closed	-$392K	–	38
2014 Q4	$392K	Buy	+21,322	New	+$458K	0.19%	28
2014 Q3	–	Sell	-16,779	Closed	-$612K	–	44
2014 Q2	$612K	Sell	16,779 -74,437	-82%	-$3M	0.27%	37
2014 Q1	$4.18M	Sell	91,216 -8,784	-9%	-$410K	2.18%	20
2013 Q4	$3.89M	Buy	100,000 +60,099	+151%	+$2.53M	2.75%	18
2013 Q3	$1.81M	Buy	+39,901	New	+$2.05M	1.25%	22

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MTWSIF

Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Great Point Partners's PLX Position: Q1 2015 in Review

Great Point Partners sold out of Protalix BioTherapeutics (PLX) in Q1 2015, closing a stake of 21,322 shares — an estimated $392K sold.

Great Point Partners first reported a position in PLX in Q3 2013 and held it in 5 quarters. The position peaked at $4.18M in Q1 2014. 37 funds tracked by Wall St. Rank hold PLX as of Q1 2015.

Great Point Partners reported no remaining Protalix BioTherapeutics position as of Q1 2015 after selling out during the quarter.
Great Point Partners sold 21,322 Protalix BioTherapeutics shares in Q1 2015, an estimated $392K.
Great Point Partners first reported a position in Protalix BioTherapeutics in Q3 2013 and held it in 5 quarters.
Great Point Partners's Protalix BioTherapeutics position peaked at $4.18M in Q1 2014.
37 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2015.

Based on Great Point Partners's 13F filing for Q1 2015, filed 15 May 2015.